Venous Thromboembolism Treatment Market - By Application, By Treatment Type, By Age Group, By End Use - Global Forecast, 2025 - 2034

Venous Thromboembolism Treatment Market Size

The global venous thromboembolism treatment market was estimated at USD 3.3 billion in 2024. The market is expected to grow from USD 3.4 billion in 2025 to USD 5.4 billion in 2034, at a CAGR of 5.2%, according to the latest report published by Global Market Insights Inc.

The rising prevalence of venous thromboembolism (VTE) is significantly driving demand for specialized anticoagulant therapies, thrombolytic agents, and mechanical prophylactic devices. According to the American Heart Association, thrombosis including VTE, heart attacks, and strokes is responsible for 1 in 4 deaths globally, underscoring its status as a major public health concern. This demand is particularly noticeable among elderly individuals, cancer patients, and those with limited mobility or recovering from surgery, who are at elevated risk for VTE. Despite its impact, public awareness of VTE remains low compared to other cardiovascular conditions, highlighting the urgent need for education and preventive strategies.
 

The aging global population is increasingly recognized as a major driver of market growth in venous thromboembolism (VTE) management. According to the World Health Organization, by 2030, 1 in 6 people worldwide will be aged 60 years or older, with the number rising from 1 billion in 2020 to 1.4 billion. This demographic shift significantly escalates the risk of VTE, particularly among individuals aged 65 and above, due to age-related physiological changes and comorbidities.
 

Moreover, growing awareness of post-thrombotic syndrome (PTS) a chronic and debilitating complication of deep vein thrombosis (DVT) is further stimulating demand for advanced therapeutic solutions. PTS affects 20% to 50% of patients within 1 to 2 years of a DVT episode, often leading to persistent pain, swelling, and in severe cases, venous ulcers. Its impact on quality of life and physical functionality is comparable to chronic conditions such as heart failure or cancer, making it a critical concern in long-term VTE management.
 

Venous thromboembolism treatment refers to a specialized class of anticoagulants, thrombolytic drugs, and vascular devices designed to manage or prevent blood clots in veins. These treatments differ from general cardiovascular therapies by targeting the coagulation cascade, clot dissolution, and vascular clearance, and are prescribed based on age, immune status, comorbidities, and disease severity.
 

Key players such as Pfizer, Bayer, Boehringer Ingelheim, Boston Scientific, Medtronic, and AngioDynamics lead the market with robust product portfolios and strong research and development pipelines. These companies drive innovation, expand healthcare partnerships, and raise awareness, positioning venous thromboembolism therapeutics as a rapidly growing segment in the cardiovascular treatment landscape.
 

The market has shown consistent growth, rising from USD 2.9 billion in 2021 to USD 3.1 billion in 2023, driven by increased healthcare spending, regulatory approvals, and innovations in biosynthetic and microbial venous thromboembolism treatment production. The growing adoption of low weight venous thromboembolism treatment due to its improved safety and ease of administration is reshaping treatment protocols.
 

This growth was supported by increased awareness of venous thromboembolism symptoms and risks, expansion of hospital-based prevention programs, and the adoption of telehealth platforms for remote anticoagulant management. Additionally, the rise of direct-to-consumer pharmaceutical platforms has improved access to oral anticoagulants and compression therapy, enabling earlier intervention and better patient outcomes.
 

Venous thromboembolism treatments play a critical role in reducing disease burden, improving patient outcomes, and enhancing public health strategies.
 

Venous Thromboembolism Treatment Market Trends

• Increasing awareness of venous thromboembolism (VTE) risks and complications is driving the adoption of preventive and therapeutic solutions across global healthcare systems. Both patients and healthcare providers are recognizing the serious consequences of untreated deep vein thrombosis (DVT) and pulmonary embolism (PE), leading to heightened demand for anticoagulants, compression therapies, and thrombectomy devices. These interventions are crucial for reducing long-term complications and improving patient outcomes.
   
• The aging population and rise in sedentary lifestyles are significantly contributing to market growth. Older adults and individuals with limited mobility face a higher risk of clot formation, prompting increased use of prophylactic treatments in hospitals, rehabilitation centers, and home care settings. This trend is accelerating the need for accessible and effective VTE prevention strategies across diverse care environments.
   
• Advancements in anticoagulant formulations and thrombectomy technologies are enhancing treatment precision and safety. Innovations such as extended-release oral anticoagulants, AI-assisted clot removal systems, and minimally invasive devices are improving patient compliance, reducing adverse events, and streamlining care delivery.
   
• Hospital-based VTE prevention protocols and surgical recovery programs are expanding the use of compression systems and injectable anticoagulants. Healthcare providers are increasingly integrating VTE prevention into standard post-operative care, particularly in orthopedic, cardiovascular, and oncology-related procedures, to mitigate risks and improve recovery outcomes.
   
• Digital health platforms and telemedicine are revolutionizing access to VTE treatments and monitoring. Remote consultations, e-prescriptions, and mobile health applications are enabling personalized anticoagulation management, enhancing treatment adherence, and extending care to underserved and rural populations.
   
• There is a growing demand for personalized, risk-based treatment strategies tailored to individual patient profiles. Clinicians are increasingly using genetic, lifestyle, and comorbidity data to guide therapy selection, dosage, and duration, driving innovation in precision medicine.
   
• Emerging markets are witnessing increased investment in venous thromboembolism awareness, diagnostics, and treatment infrastructure. Governments and private healthcare providers are launching campaigns, upgrading facilities, and training professionals to address the rising burden of venous thromboembolism in Asia-Pacific, Latin America, and Africa.
   
• Collaborations between pharmaceutical companies, device manufacturers, and healthcare institutions are accelerating product development and market penetration. Joint ventures and strategic alliances are helping firms expand their portfolios, conduct clinical trials, and improve distribution networks globally.
   

Venous Thromboembolism Treatment Market Analysis

Based on treatment type, the venous thromboembolism treatment market is categorized into devices and drug type. The drug type segment accounted for 65.5% of the market in 2024 which is stimulated due to widespread use of anticoagulants and thrombolytics in hospital and outpatient settings. The segment is expected to exceed USD 3.5 billion by 2034, growing at a CAGR of 5.1% during the forecast period.
 

• The drug type is further bifurcated into anticoagulants and thrombolytics. The anticoagulants sub-segment further categorizes into direct oral anticoagulants, heparin and vitamin K antagonists.
   
• The drug type segment dominates the global venous thromboembolism (VTE) treatment market, primarily due to the favorable pharmacokinetic properties of modern anticoagulants. These include predictable anticoagulant responses, longer half-lives, and reduced need for frequent monitoring, making them highly suitable for both acute and long-term management.
   
• Anticoagulants play a central role in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). Their use spans across various patient groups, including those recovering from surgery, individuals with cancer-associated thrombosis, and patients with chronic mobility limitations.
   
• The shift toward direct oral anticoagulants (DOACs) has significantly improved patient compliance and reduced the need for frequent monitoring. According to the American College of Cardiology and American Society of Hematology, DOACs such as apixaban, rivaroxaban, and dabigatran are recommended as first-line treatments for acute deep vein thrombosis (DVT) and pulmonary embolism (PE) in most patients. Their predictable pharmacokinetics, fixed dosing, and lower risk of drug interactions make them preferable over traditional vitamin K antagonists.
   
• Affordability, accessibility, and clinical familiarity also contribute to the dominance of anticoagulants and thrombolytics in the VTE treatment market. Physicians and healthcare providers are well-versed in their use, and the availability of generic formulations has expanded access, particularly in emerging markets. This widespread adoption supports both acute care and long-term management strategies for diverse patient populations.
   
• Moreover, the devices segment is expected to grow at a CAGR of 5.3%. This segment is gaining traction due to its ability to remove clots without systemic anticoagulation, making it especially valuable for patients with contraindications to drug therapy. This approach offers a safer alternative for individuals at high risk of bleeding or those unable to tolerate anticoagulants.
   

Based on application, the venous thromboembolism treatment market is segmented into deep vein thrombosis and pulmonary embolism. The deep vein thrombosis segment generated USD 2 billion in 2024 and is expected to reach USD 3.3 billion by 2034.
 

• Deep vein thrombosis dominates the venous thromboembolism treatment market, accounting for the largest share.
   
• Deep vein thrombosis occurs when a blood clot forms in the deep veins, typically in the legs, and can lead to serious complications such as pulmonary embolism if not treated promptly.
   
• The high prevalence of deep vein thrombosis (DVT) is driven by risk factors such as prolonged immobility, obesity, smoking, and underlying medical conditions like cancer. In response, healthcare providers emphasize early diagnosis and timely intervention using anticoagulants, compression therapy, and, in select cases, mechanical thrombectomy devices to prevent complications and improve outcomes.
   
• Pharmaceutical and medical device companies are actively investing in innovative therapies tailored to DVT management. These include next-generation oral anticoagulants and minimally invasive devices designed to enhance treatment efficacy, improve patient recovery, and reduce hospital stays ultimately contributing to better long-term care and cost efficiency.
   
• The pulmonary embolism (PE) segment is projected to grow steadily, driven by the critical and life-threatening nature of the condition, which demands immediate medical intervention. Pulmonary embolism occurs when a blood clot dislodges and travels to the lungs, obstructing pulmonary arteries and potentially leading to respiratory failure or death. This urgency has led to increased focus on rapid diagnosis and treatment, including anticoagulants, thrombolytics, and mechanical interventions.
   

Based on age group, the venous thromboembolism treatment market is segmented into adults and geriatric. The geriatric segment accounted for the highest market share and is growing with the significant CAGR of 5.3% during the forecast period.
 

• The geriatric population dominates the venous thromboembolism (VTE) treatment market, primarily due to their higher vulnerability to blood clots. Age-related physiological changes, reduced mobility, and the presence of chronic conditions such as heart disease and cancer significantly increase the risk of VTE among older adults.
• According to ScienceDirect, the incidence of VTE rises exponentially with age, with individuals aged 65 and older accounting for over 60% of VTE events. This trend is further amplified in long-term care settings, where multimorbidity and immobility are common.
   
• Treatments that require less frequent monitoring and offer better safety profiles—such as direct oral anticoagulants are especially important for this age group. Additionally, healthcare systems are placing greater emphasis on geriatric care, further supporting the expansion of this segment.
   
• The segment’s dominance is also influenced by lower immunity and increased susceptibility to infections and diseases among older adults, which heightens the need for proactive and tailored VTE management strategies.
   
• The adult segment also holds a significant share of the venous thromboembolism (VTE) treatment market, driven by lifestyle-related risk factors such as sedentary behavior, obesity, and the rising number of surgical procedures. While adults generally experience fewer health complications than the elderly, they still require effective treatment options particularly in cases involving post-operative recovery or cancer-associated thrombosis. This has led to increased utilization of anticoagulants, compression therapies, and minimally invasive devices within this demographic.
   

Based on end use, the venous thromboembolism treatment market is categorized into hospitals, catheterization laboratories, ambulatory surgical centers (ASCs) and other end users. The hospitals segment accounted for the highest market share of 58.5% in 2024 due to easy availability and convenience, hospitals are a primary channel in the venous thromboembolism treatment market.  
 

• Hospitals dominate the venous thromboembolism (VTE) treatment market, primarily due to their high patient volume, extensive use of anticoagulants in surgical and emergency care, and access to advanced treatment protocols. Their centralized infrastructure allows for rapid response and comprehensive management of both deep vein thrombosis (DVT) and pulmonary embolism (PE).
   
• Advanced diagnostic capabilities in hospitals such as Doppler ultrasound, CT pulmonary angiography, and D-dimer testing—enable timely and accurate detection of VTE, which is critical for initiating appropriate treatment and preventing complications.
   
• Hospitals also offer immediate access to a wide range of therapeutic options, including anticoagulants, thrombolytic agents, and surgical interventions like thrombectomy. This comprehensive approach is essential for managing life-threatening VTE events and improving patient outcomes.
   
• Catheterization laboratories play a specialized role in the venous thromboembolism (VTE) treatment landscape, particularly in performing minimally invasive procedures such as catheter-directed thrombolysis and thrombectomy. These labs are essential for patients who require targeted interventions to dissolve or remove clots, especially in cases where systemic anticoagulation is contraindicated or insufficient. Their precision-based approach contributes to faster recovery and reduces risk of complications.
   

North America Venous Thromboembolism Treatment Market

The North America venous thromboembolism treatment market dominated the global market with a market share of 40.1% in 2024.
 

• The region benefits from a robust healthcare system with access to specialized hospitals, diagnostic technologies, and trained professionals, enabling early detection and comprehensive treatment of VTE cases.
   
• Government and nonprofit campaigns have increased awareness about VTE symptoms and prevention in the region. This leads to earlier diagnosis and treatment, boosting demand for therapeutic products and services.
   
• Moreover, ongoing research and development by pharmaceutical and medical device companies in North America leads to new drugs and technologies, enhancing treatment efficacy and expanding the market with innovative solutions.
   

The U.S. venous thromboembolism treatment market was valued at USD 1.05 billion and USD 1.09 billion in 2021 and 2022, respectively. The market size reached USD 1.17 billion in 2024, growing from USD 1.13 billion in 2023.
 

• The U.S. is a major consumer of venous thromboembolism (VTE) treatment solutions, driven by a high volume of cardiovascular surgeries and chronic disease cases. According to the CDC, up to 900,000 people in the U.S. are affected by VTE annually, with 60,000–100,000 deaths attributed to deep vein thrombosis (DVT) and pulmonary embolism (PE).
   
• Supportive FDA regulatory frameworks and reimbursement policies have accelerated the approval and adoption of both branded and generic VTE treatment products. For example, drugs like Pradaxa (dabigatran etexilate) have received expanded indications for treating and preventing DVT and PE, including in pediatric populations.
   
• Hospitals and homecare settings increasingly utilize prefilled syringes and autoinjectors, supporting safe and efficient anticoagulant therapy, especially for patients requiring long-term management.
   
• The U.S. market benefits from advanced manufacturing infrastructure, enabling rapid scale-up and innovation in VTE therapy production. This facilitates timely access to cutting-edge treatments and supports ongoing research and development efforts.
   

Europe Venous Thromboembolism Treatment Market
 

Europe market accounted for USD 863.9 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Rising incidence of venous thromboembolism (VTE) particularly among aging populations in Germany, France, and Italy is driving sustained demand for VTE treatment therapies across both inpatient and outpatient settings.
   
• According to a study published in Thrombosis and Haemostasis, over one million VTE events or deaths occur annually in just six European countries, underscoring the severity of the condition and the need for effective prevention and treatment strategies.
   
• The burden includes hundreds of thousands of cases of deep vein thrombosis (DVT), pulmonary embolism (PE), and VTE-related deaths, many of which are hospital-acquired and potentially preventable with timely intervention.
   

Germany venous thromboembolism treatment market is anticipated to witness considerable growth over the analysis period.
 

• The high prevalence of cardiovascular diseases in Germany, is increasing the market demand. According to a study by NIH, 54% female in 17 centers were found to be suffering from acute deep vein thrombosis or pulmonary embolism, stimulating the demand for anticoagulant therapies particularly in aging populations with chronic conditions.
   
• Growing shift toward preventive healthcare, supported by national cardiology guidelines and early screening programs, is escalating the market demand for venous thromboembolism treatment.
   
• The country has a well-established healthcare infrastructure, which supports the recommendation and adoption of venous thromboembolism treatment for targeted drug therapies.
   
• In addition, Germany’s robust pharmaceutical and hospital network, including specialized clinics, pharmacies, and digital health platforms, ensures wide availability and accessibility of venous thromboembolism treatment treatments.
   

Asia Pacific Venous Thromboembolism Treatment Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 5.5% during the analysis timeframe.
 

• Key Asia-Pacific markets including China, India, Japan, South Korea, and Australia are experiencing rising incidence of venous thromboembolism (VTE), driven by aging populations, lifestyle-related risk factors, and increasing healthcare investments. This trend is stimulating demand for advanced therapeutics, including direct oral anticoagulants, thrombolytics, and mechanical devices.
   
• The expansion of hospitals, diagnostic centers, and respiratory care clinics, particularly in urban areas, is further accelerating the growth of the VTE treatment market. Improved access to healthcare infrastructure and specialized services is enabling earlier diagnosis and more effective management of VTE across diverse patient populations.
   

China venous thromboembolism treatment market is predicted to grow significantly over the forecast period.
 

• China is experiencing a rise in venous thromboembolism (VTE) cases, driven by rapid urbanization and healthcare modernization. Increased surgical procedures, sedentary lifestyles, and aging demographics are contributing to the growing burden of VTE across both urban and rural populations.
   
• Pregnancy-related VTE is also on the rise in China, with a recent study in Wuhan reporting an incidence of 1.63 per 1,000 pregnancies, particularly during the postpartum period. Key risk factors include immobility, systemic infections, obesity, and hypertensive disorders of pregnancy.
   
• The Chinese government is actively investing in healthcare infrastructure and digital platforms to improve access to VTE treatment and prevention. Initiatives under the 14th Five-Year Plan include the development of smart hospitals, digital health services, and AI-enabled clinical tools to enhance diagnosis and care delivery.
   

Latin America Venous Thromboembolism Treatment Market
 

Brazil is experiencing significant growth in the Latin America market due to the increasing demand for thrombosis solutions and long-term care.
 

• The rising incidence of venous thromboembolism (VTE) in Brazil is stimulating market demand for treatment solutions. According to Jornal Vascular Brasileiro, the country reports 50 to 200 cases of VTE per 100,000 individuals annually, with higher prevalence in southern regions due to colder temperatures, which are associated with increased clot formation.
   
• Government-led cardiovascular care initiatives are strengthening thrombosis management across Brazil. Programs under the Brazilian Unified Health System (SUS) and national anticoagulation protocols are promoting consistent demand for VTE therapies in public hospitals. These include improved access to guideline-recommended medications and structured emergency care pathways.
   
• Urgent and emergency care programs, such as SAMU and regional cardiovascular networks, have demonstrated significant improvements in clinical outcomes, particularly in reducing morbidity and mortality from conditions like pulmonary embolism and deep vein thrombosis
   

Middle East and Africa Venous Thromboembolism Treatment Market
 

Saudi Arabia market is poised to witness substantial growth in Middle East and Africa market during the forecast period.
 

• Saudi Arabia’s Vision 2030 is actively driving the expansion of cardiovascular care infrastructure, including the development of specialized clinics, mobile health units, and diagnostic laboratories. The initiative aims to reduce the clinical and economic burden of cardiovascular diseases (CVDs) and venous thromboembolism (VTE) through enhanced public health measures, digital health integration, and national registries.
   
• National programs for thrombosis prevention and anticoagulation therapy are being implemented across public hospitals, reflecting strong governmental support for VTE management. These programs promote consistent demand for both branded and generic anticoagulant therapies, especially in high-risk populations.
   

Venous Thromboembolism Treatment Market Share

Leading companies such as Pfizer, Bayer, Johnson & Johnson, Sanofi, and Bristol Myers Squibb collectively hold ~62% of the market share in the global venous thromboembolism (VTE) treatment market. These companies maintain dominance through extensive anticoagulant portfolios, strategic collaborations, regulatory strength, and continuous innovation. Pfizer holds a strong competitive advantage with its VTE treatment offerings, including Eliquis, which is widely adopted across hospitals and outpatient care settings.
 

Bayer maintains a competitive edge with Xarelto, a leading oral anticoagulant supported by broad clinical use and global distribution. Emerging and niche players such as Boston Scientific, AngioDynamics, Cardinal Health, Covidien (Medtronic), Daesung Maref, Argon Medical Products, Cook Medical, and Philips Healthcare are gaining traction with innovative thrombectomy systems, compression devices, and vascular support technologies. These companies contribute to market growth through specialized devices, regional distribution networks, and a focus on minimally invasive solutions. Pharmaceutical firms such as Boehringer Ingelheim, Novartis, Daiichi Sankyo, and GlaxoSmithKline support the broader therapeutic landscape through advanced anticoagulant formulations, generics, and diagnostic tools.
 

Venous Thromboembolism Treatment Market Companies

Few prominent players operating in the venous thromboembolism treatment industry includes:

• AngioDynamics
• Argon Medical Products
• Bayer
• Boehringer Ingelheim
• Boston Scientific
• Bristol Myers Squibb
• Cardinal Health
• Cook Medical
• Covidien (Medtronic)
• Daesung Maref
• Daiichi Sankyo
• GlaxoSmithKline
• Johnson & Johnson
• Novartis
• Pfizer
• Philips Healthcare
• Sanofi
   
• Pfizer

Pfizer leads the venous thromboembolism treatment market with a share of ~14.2% and a strong portfolio centered; through its globally recognized anticoagulant Eliquis, supported by strong clinical data, strategic partnerships, and integration with digital health platforms. Its focus on patient adherence and real-world evidence enhances its value across hospital and outpatient settings.
 

• Bayer

Bayer maintains a strong position with Xarelto, a widely adopted oral anticoagulant backed by extensive clinical trials and global reach. Its emphasis on cardiovascular health, combined with innovation in extended-release formulations and risk-based therapy, reinforces its leadership in the venous thromboembolism space.
 

• Johnson & Johnson

Johnson & Johnson supports venous thromboembolism care through Janssen’s Xarelto and a diversified cardiovascular portfolio. Its strategic investments in thrombosis research, scalable delivery systems, and digital health integration strengthen its role in prevention and long-term management of venous thromboembolism.
 

Venous Thromboembolism Treatment Industry News

• In February 2025, Novartis acquired Anthos Therapeutics, adding abelacimab a late-stage monoclonal antibody targeting Factor XI to its cardiovascular pipeline. The acquisition strengthened Novartis position in anticoagulation portfolio.
   
• In January 2025, Stryker acquired Inari Medical adding mechanical thrombectomy solutions for deep vein thrombosis and pulmonary embolism to its portfolio. This expanded presence in the venous thromboembolism treatment segment.
   
• In June 2024, Alembic Pharmaceuticals received U.S. FDA approval for its generic Dabigatran Etexilate Capsules in 75 mg and 150 mg strengths. This approval expanded presence in the anticoagulant segment.
   
• In July 2021, Surmodics acquired Vetex Medical Limited, adding the FDA-cleared ReVene Thrombectomy Catheter to its portfolio for venous clot removal. This acquisition strengthened Surmodics position expanding its capabilities in both arterial and venous thrombosis.
   

The venous thromboembolism treatment drugs market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Devices
  • Compression system
  • Thrombectomy systems
  • IVC filters
  • Stockings
  • Other devices
• Drug type
  • Anticoagulants        
    • Direct oral anticoagulants
    • Heparin
    • Vitamin K antagonists
  • Thrombolytics

Market, By Application

• Deep vein thrombosis
• Pulmonary embolism

Market, By Age Group

• Adult
• Geriatric

Market, By End Use

• Hospitals
• Catheterization laboratories
• Ambulatory surgical centers (ASCs)
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE